Get the Stockscreener App
1.76
1.15%
0.02
Pre-market:
1.77
0.01
+0.57%
Geron Corp stock is traded at $1.76, with a volume of 12.66M.
It is up +1.15% in the last 24 hours and down -38.68% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$1.74
Open:
$1.74
24h Volume:
12.66M
Relative Volume:
1.03
Market Cap:
$1.12B
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-5.50
EPS:
-0.32
Net Cash Flow:
$-216.50M
1W Performance:
-31.52%
1M Performance:
-38.68%
6M Performance:
-62.95%
1Y Performance:
-12.00%
1-Day Range:
$1.70
$1.79
1-Week Range:
$1.4601
$2.5756
52-Week Range:
$1.4601
$5.34
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.76 | 1.12B | 29.48M | -201.19M | -216.50M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 123.21B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 31.94B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.00B | 3.32B | -860.46M | -1.04B | -8.32 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
Geron (NASDAQ:GERN) Trading Up 9%Here's Why - MarketBeat
Geron (NASDAQ:GERN) Price Target Lowered to $4.00 at Stifel Nicolaus - MarketBeat
Geron (NASDAQ:GERN) Lowered to Neutral Rating by B. Riley - MarketBeat
Geron (GERN) to Release Earnings on Wednesday - MarketBeat
Geron (NASDAQ:GERN) Issues Earnings Results, Hits Estimates - MarketBeat
Geron (NASDAQ:GERN) Announces Quarterly Earnings Results - MarketBeat
Geron (NASDAQ:GERN) Cut to Neutral at HC Wainwright - MarketBeat
Stifel cuts Geron stock target to $4, maintains buy rating - Investing.com
Stifel cuts Geron stock target to $4, maintains buy rating By Investing.com - Investing.com South Africa
Geron price target lowered to $4 from $6 at Scotiabank - TipRanks
Scotiabank cuts Geron stock target to $4, keeps outperform rating - Investing.com India
Geron Corporation (NASDAQ:GERN) Q4 2024 Earnings Call Transcript - Insider Monkey
Scotiabank cuts Geron stock target to $4, keeps outperform rating By Investing.com - Investing.com South Africa
We Think Geron (NASDAQ:GERN) Can Afford To Drive Business Growth - Yahoo Finance
We're Hopeful That Geron (NASDAQ:GERN) Will Use Its Cash Wisely - Simply Wall St
GERON CORP SEC 10-K Report - TradingView
Geron Corporation Reports Strong 2024 Financial Results - TipRanks
Geron stock plunges 30% following Q4 report - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Geron CorporationGERN - PR Newswire
Geron (GERN) Stock Declines Amid Weak Rytelo Outlook - GuruFocus.com
Why Geron Stock Is Plummeting Today - MSN
Geron: Q4 Earnings Snapshot - mySA
Wedbush Lowers Geron's Price Target to $7 From $8, Outperform Rating Maintained - Marketscreener.com
Geron stock rating downgraded on flat revenue outlook By Investing.com - Investing.com South Africa
Geron Inc.: Strategic Market Position and Rytelo’s Potential Justify Buy Rating - TipRanks
TD Cowen cuts Geron stock price target to $5, maintains Buy rating - Investing.com
HC Wainwright Downgrades Geron to Neutral From Buy -February 26, 2025 at 12:35 pm EST - Marketscreener.com
Geron (GERN) Q4 2024 Earnings Call Transcript - Yahoo
Geron: Rytelo's Market Share Concerns Justified As 3L Dominates Early Sales (NASDAQ:GERN) - Seeking Alpha
Geron earnings missed by $0.01, revenue fell short of estimates - Investing.com India
Geron (NASDAQ:GERN) Hits New 1-Year LowTime to Sell? - MarketBeat
Geron stock plunges 30% amid Rytelo sales concerns (update) - MSN
Geron Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Geron Corporation Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Geron reports Q4 EPS (4c), consensus (5c) - TipRanks
Geron stock tumbles on disappointing guidance By Investing.com - Investing.com Australia
Geron stock tumbles on disappointing guidance - Investing.com
Earnings call transcript: Geron Q4 2024 misses EPS, stock plummets - Investing.com
Geron stock touches 52-week low at $1.63 amid market fluctuations - Investing.com
Geron (GERN) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Geron's Q4 Net Loss Narrows, Revenue Rises -February 26, 2025 at 07:59 am EST - Marketscreener.com
Geron: Q4 Earnings Snapshot -February 26, 2025 at 07:52 am EST - Marketscreener.com
Geron Corporation Q4 Loss Decreases, Beats Estimates - Nasdaq
Earnings Flash (GERN) GERON CORPORATION Posts Q4 Revenue $47.5M, vs. FactSet Est of $61.8M - Marketscreener.com
Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Bakersfield Californian
Can Geron's $47.5M RYTELO Revenue Transform This Cancer Treatment Company? - StockTitan
HC Wainwright & Co. Downgrades Geron (GERN) - MSN
Geron (GERN) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
GERNGeron Corp Latest Stock News & Market Updates - StockTitan
Geron to Participate at Upcoming Investor Conferences in March 2025 - Business Wire
Geron Co. (NASDAQ:GERN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):